Table 1.
Clinical baseline characteristics among different status of the HRD score in HER2-low TCGA-EBC.
| TCGA HER2-low clinical characteristic |
All patients (n = 531) | Number of patients (%) | |||
|---|---|---|---|---|---|
| HRD ≤ 8 (n = 140) | HRD 9-33 (n = 262) | HRD > 33 (n = 129) | P-value | ||
| Age (years) | <0.001 | ||||
| < 60 | 280 (52.73%) | 52 (37.14%) | 145 (55.34%) | 83 (64.34%) | |
| ≥ 60 | 251 (47.27%) | 88 (62.86%) | 117 (44.66%) | 46 (35.66%) | |
| TNM stage | 0.111 | ||||
| Stages I-II | 384 (72.32%) | 94 (67.14%) | 200 (76.34%) | 90 (69.77%) | |
| Stage III | 147 (27.68%) | 46 (32.86%) | 62 (23.66%) | 39 (30.23%) | |
| Tumor size | <0.001 | ||||
| T1-T2 | 441 (83.05%) | 98 (70.00%) | 225 (85.88%) | 118 (91.47%) | |
| T3-T4 | 90 (16.95%) | 42 (30.00%) | 37 (14.12%) | 11 (8.53%) | |
| Lymph nodes | 0.003 | ||||
| N0-N1 | 432 (81.36%) | 123 (87.86%) | 216 (82.48%) | 93 (72.09%) | |
| N2-N3 | 99 (18.64%) | 17 (12.14%) | 46 (17.56%) | 36 (27.91%) | |
| IHC | 0.577 | ||||
| 1+ | 332 (62.52%) | 91 (65.00%) | 158 (60.31%) | 83 (64.34%) | |
| 2+ | 199 (37.48%) | 49 (35.00%) | 104 (39.69%) | 46 (35.66%) | |
| HR status | <0.001 | ||||
| Negative | 91 (17.14%) | 4 (2.86%) | 30 (11.45%) | 57 (44.19%) | |
| Positive | 440 (82.86%) | 136 (97.14%) | 232 (88.55%) | 72 (55.81%) | |
| HRRGs mutations status | 0.001 | ||||
| NO | 325 (61.21%) | 98 (70.00%) | 164 (62.6%) | 63 (48.84%) | |
| YES | 80 (15.07%) | 12 (8.57%) | 35 (13.36%) | 33 (25.58%) | |
| NA | 126 (23.73%) | 30 (21.43%) | 63 (24.05%) | 33 (25.58%) | |
| BRCA1/2 mutation status | 0.015 | ||||
| NO | 388 (73.07%) | 109 (77.86%) | 193 (73.66%) | 86 (66.67%) | |
| YES | 17 (3.20%) | 1 (0.71%) | 6 (2.29%) | 10 (7.75%) | |
| NA | 126 (23.73%) | 30 (21.43%) | 63 (24.05%) | 33 (25.58%) | |
Abbreviations: BRCA, breast cancer susceptibility gene; HR, hormone receptor; HRD, homologous recombination defect score; HRRGs, homologous recombination repair genes; IHC, immunohistochemistry; TCGA, The Cancer Genome Atlas dataset.